196 related articles for article (PubMed ID: 23150596)
1. Sprouty genes function in suppression of prostate tumorigenesis.
Schutzman JL; Martin GR
Proc Natl Acad Sci U S A; 2012 Dec; 109(49):20023-8. PubMed ID: 23150596
[TBL] [Abstract][Full Text] [Related]
2. Coordinated activity of Spry1 and Spry2 is required for normal development of the external genitalia.
Ching ST; Cunha GR; Baskin LS; Basson MA; Klein OD
Dev Biol; 2014 Feb; 386(1):1-11. PubMed ID: 24361260
[TBL] [Abstract][Full Text] [Related]
3. The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision.
Luchman HA; Benediktsson H; Villemaire ML; Peterson AC; Jirik FR
PLoS One; 2008; 3(12):e3940. PubMed ID: 19081794
[TBL] [Abstract][Full Text] [Related]
4. Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression.
Patel R; Gao M; Ahmad I; Fleming J; Singh LB; Rai TS; McKie AB; Seywright M; Barnetson RJ; Edwards J; Sansom OJ; Leung HY
J Clin Invest; 2013 Mar; 123(3):1157-75. PubMed ID: 23434594
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer.
Couto SS; Cao M; Duarte PC; Banach-Petrosky W; Wang S; Romanienko P; Wu H; Cardiff RD; Abate-Shen C; Cunha GR
Differentiation; 2009 Jan; 77(1):103-11. PubMed ID: 19281769
[TBL] [Abstract][Full Text] [Related]
6. Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis.
Zhong C; Saribekyan G; Liao CP; Cohen MB; Roy-Burman P
Cancer Res; 2006 Feb; 66(4):2188-94. PubMed ID: 16489020
[TBL] [Abstract][Full Text] [Related]
7. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT
Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963
[TBL] [Abstract][Full Text] [Related]
8. Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma.
Fong CW; Chua MS; McKie AB; Ling SH; Mason V; Li R; Yusoff P; Lo TL; Leung HY; So SK; Guy GR
Cancer Res; 2006 Feb; 66(4):2048-58. PubMed ID: 16489004
[TBL] [Abstract][Full Text] [Related]
9. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.
Song H; Zhang B; Watson MA; Humphrey PA; Lim H; Milbrandt J
Oncogene; 2009 Sep; 28(37):3307-19. PubMed ID: 19597465
[TBL] [Abstract][Full Text] [Related]
10. Additive Effect of Zfhx3/Atbf1 and Pten Deletion on Mouse Prostatic Tumorigenesis.
Sun X; Xing C; Fu X; Li J; Zhang B; Frierson HF; Dong JT
J Genet Genomics; 2015 Jul; 42(7):373-82. PubMed ID: 26233892
[TBL] [Abstract][Full Text] [Related]
11. Cosuppression of Sprouty and Sprouty-related negative regulators of FGF signalling in prostate cancer: a working hypothesis.
Assinder SJ; Beniamen D; Lovicu FJ
Biomed Res Int; 2015; 2015():827462. PubMed ID: 26075267
[TBL] [Abstract][Full Text] [Related]
12. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
13. Deletion of atbf1/zfhx3 in mouse prostate causes neoplastic lesions, likely by attenuation of membrane and secretory proteins and multiple signaling pathways.
Sun X; Fu X; Li J; Xing C; Frierson HF; Wu H; Ding X; Ju T; Cummings RD; Dong JT
Neoplasia; 2014 May; 16(5):377-89. PubMed ID: 24934715
[TBL] [Abstract][Full Text] [Related]
14. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.
Blando J; Portis M; Benavides F; Alexander A; Mills G; Dave B; Conti CJ; Kim J; Walker CL
Am J Pathol; 2009 May; 174(5):1869-79. PubMed ID: 19395652
[TBL] [Abstract][Full Text] [Related]
15. Loss of Ceacam1 promotes prostate cancer progression in Pten haploinsufficient male mice.
Liu J; Muturi HT; Khuder SS; Helal RA; Ghadieh HE; Ramakrishnan SK; Kaw MK; Lester SG; Al-Khudhair A; Conran PB; Chin KV; Gatto-Weis C; Najjar SM
Metabolism; 2020 Jun; 107():154215. PubMed ID: 32209360
[TBL] [Abstract][Full Text] [Related]
16. Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model.
Ai J; Pascal LE; O'Malley KJ; Dar JA; Isharwal S; Qiao Z; Ren B; Rigatti LH; Dhir R; Xiao W; Nelson JB; Wang Z
Oncogene; 2014 May; 33(18):2286-94. PubMed ID: 23708662
[TBL] [Abstract][Full Text] [Related]
17. PTEN inhibits BMI1 function independently of its phosphatase activity.
Fan C; He L; Kapoor A; Rybak AP; De Melo J; Cutz JC; Tang D
Mol Cancer; 2009 Nov; 8():98. PubMed ID: 19903340
[TBL] [Abstract][Full Text] [Related]
18. Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway.
Hanafusa H; Torii S; Yasunaga T; Nishida E
Nat Cell Biol; 2002 Nov; 4(11):850-8. PubMed ID: 12402043
[TBL] [Abstract][Full Text] [Related]
19. The tumor suppressor PTEN is necessary for human Sprouty 2-mediated inhibition of cell proliferation.
Edwin F; Singh R; Endersby R; Baker SJ; Patel TB
J Biol Chem; 2006 Feb; 281(8):4816-22. PubMed ID: 16371366
[TBL] [Abstract][Full Text] [Related]
20. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
Tan M; Xu J; Siddiqui J; Feng F; Sun Y
Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
